Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Cost of Revenue (2022 - 2025)

Cannabis Bioscience International Holdings' Cost of Revenue history spans 4 years, with the latest figure at $10500.0 for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 34.56% year-over-year to $10500.0; the TTM value through Nov 2025 reached $42584.0, up 12.5%, while the annual FY2025 figure was $40106.0, 12.05% down from the prior year.
  • Cost of Revenue for Q4 2025 was $10500.0 at Cannabis Bioscience International Holdings, up from $8143.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $24120.0 in Q1 2023 and bottomed at $4545.0 in Q2 2025.
  • The 4-year median for Cost of Revenue is $9878.0 (2024), against an average of $11658.8.
  • The largest annual shift saw Cost of Revenue surged 112.86% in 2023 before it plummeted 53.99% in 2025.
  • A 4-year view of Cost of Revenue shows it stood at $7090.0 in 2022, then soared by 112.86% to $15092.0 in 2023, then plummeted by 48.3% to $7803.0 in 2024, then skyrocketed by 34.56% to $10500.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIH's Cost of Revenue are $10500.0 (Q4 2025), $8143.0 (Q3 2025), and $4545.0 (Q2 2025).